(Bloomberg)--Bristol-Myers Squibb Co.’s immune cancer therapywon approval from U.S. regulators for a broader population of lungcancer patients, a boost for a drug that’s expected to become ablockbuster.
The decision by the Food and Drug Administration camealmost three months ahead of schedule, following a trend of quickerclearances for new cancer drugs by the agency.
In March, Opdivo was approved three months ahead of planfor use in patients with advanced squamous, non-small cell lungcancer whose disease had progressed during or after tryingchemotherapy.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
